Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
In this presentation, Dr. Sungwon Lim, CEO & Co-Founder of ImpriMed, shares the latest updates from ImpriMed. ImpriMed continues to improve services to the Veterinary community adding new species and new tumor types to their offerings. Moreover, they continue to make improvements to their AI models to increase prediction power for optimizing the clinical outcomes of individual cancer patients. In a recorded session, Dr. Kevin Choy, a board-certified medical oncologist at Seattle Veterinary Specialists - BluePearl Kirkland, Washington, will present clinical cases of naïve and relapsed Canine lymphoma utilizing ImpriMed's artificial intelligence-driven anticancer drug response predictions.ImpriMed's flagship product, Personalized Prediction Profile, includes comprehensive diagnostic information and drug response predictions for canine blood cancers. ImpriMed's artificial intelligence (AI) models are trained on real-world clinical outcome data. The models predict the anticancer drugs most likely effective for a particular dog's lymphoma or leukemia based on the individual patient’s information and comprehensive testing of each patient's DNA and live cancer cells.